Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Biocytogen Pharmaceuticals and Myricx Bio Enter into Licence Agreement for ADC Development

Friday, September 08, 2023

Biocytogen Pharmaceuticals and Myricx Bio have entered into an antibody evaluation, option, and licence agreement to collaborate on the development of antibody drug conjugates (ADCs). 

This partnership leverages the strengths of both companies to create ADC drugs that have the potential to be first-in-class and best-in-class in the field of oncology.

This collaboration brings together the groundbreaking NMTi-based selective cytotoxic payloads with Biocytogen's expertise in antibody development for drug development purposes. This combination is expected to yield ADCs that can address significant clinical needs in the treatment of cancer.

NMT inhibitors represent a novel class of ADC payloads that hold promise as targeted therapies for cancer. These inhibitors work through a unique mechanism of action, which is distinct from traditional approaches to cancer treatment. ADC-NMTi has enormous potential for selectively killing cancer cells. This innovative approach offers a new way to target cancer with precision and effectiveness.

The collaboration between Biocytogen Pharmaceuticals and Myricx Bio aims to harness the strengths of both companies to develop groundbreaking ADCs that can provide significant advancements in cancer therapy. The use of NMT inhibitors as ADC payloads represents an exciting avenue for the development of selective and potent cancer treatments.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024